Pharmaceutical News

RSS

Ganeden Biotech unveils the first quick dissolving, thin strip probiotic product

Ganeden Biotech Inc., makers of the patented probiotic strain GanedenBC30(R), today announced the launch of the first quick dissolving, thin strip probiotic product. The new thin strip product is the latest in a number of innovative probiotic-enhanced products introduced by Ganeden Biotech over the past year.

16 Sep 2009

GENova Biotherapeutics and Prime BioResearch sign collaboration agreement

GENova Biotherapeutics Inc. ("GENova") today announced that it has signed a collaboration agreement with Prime BioResearch, Ltd. ("Prime BioResearch") the agreement is focused on how personalized medicine can be applied to cure cancer.

16 Sep 2009

FDA grants orphan drug status to Advanced Life Sciences' Restanza

Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Restanza(TM) (cethromycin), its novel, once daily oral antibiotic, for the prophylactic treatment of plague and tularemia. Both tularemia and plague are classified by the Centers for Disease Control as Category A Bioterrorism Agents, which is the highest priority classification.

16 Sep 2009

New book on pharmacology launched

Academic Press, a division of Elsevier, would like to announce the new book, Pharmacology: Principles and Practice, authored by Miles Hacker, William S. Messer, II and Kenneth A. Bachmann.

16 Sep 2009

Bavarian Nordic to deliver IMVAMUNE(R) vaccines

Bavarian Nordic A/S (OMX: BAVA) announced today that it has signed a contract with the military of an undisclosed EU country for the delivery of a small order for IMVAMUNE(R). The vaccines will be delivered in 2009. The size and value of the contract is undisclosed.

16 Sep 2009

Four H1N1 vaccines approved by FDA

The U.S. Food and Drug Administration announced today that it has approved four vaccines against the 2009 H1N1 influenza virus. The vaccines will be distributed nationally after the initial lots become available, which is expected within the next four weeks.

16 Sep 2009

Pre-clinical studies of ID-12 orally-bioavailable inhibitor completes

ChemDiv Inc. of San Diego, and iDialog (Intellektualniy Dialog) of Yaroslavl, Russia, announced today the successful completion of a pre-clinical development and the subsequent nomination of ID-12 as lead clinical development candidate for the treatment of chronic hepatitis C. This novel small molecule orally-bioavailable inhibitor of hepatitis C virus (HCV) blocks early stage of viral infection.

16 Sep 2009

New peptide-based cancer vaccine tested in genital cancer patients

Preventive vaccination against infectious diseases has been a major milestone for the health of modern society. The development of therapeutic vaccination against established diseases is much more difficult. For more than 100 years researchers have already tried to develop cancer vaccines and now first promising clinical results raise hopes. A summary of the most attractive new approaches gave Professor Carmen Scheibenbogen, Institut für Medizinische Immunologie, Charité-Universitätsmedizin, at a press conference in Berlin.

16 Sep 2009

Phase 3 clinical study results of bazedoxifene released

Wyeth Pharmaceuticals, a division of Wyeth, announces findings from a placebo-controlled Phase 3 study of bazedoxifene 20 mg extended to five years, which indicated a significant reduction versus placebo in new vertebral fractures in postmenopausal women with osteoporosis.

15 Sep 2009

Idera Pharmaceuticals to discuss TLR-targeted drug discovery and development programs

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its TLR-targeted drug discovery and development programs and provide a general corporate overview at the UBS Global Life Sciences Conference on Monday, September 21, 2009, at 10:30 a.m. EDT at the Grand Hyatt New York Hotel in New York City.

15 Sep 2009

Biocryst signs agreement with three partners to represent its anti-viral peramivir outside U.S.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has signed binding letters of intent with three partners who will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities, as well as for marketing and distribution of peramivir for seasonal influenza upon local regulatory approval, within their territories outside the U.S.

15 Sep 2009

Halozyme Therapeutics to present its product development pipeline

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced its participation in the UBS Global Life Sciences Conference to be held on September 21-23, 2009 in New York City.

15 Sep 2009

Neuroskin Psoriasis Relief DRTV test results announced by avVaa World Health Care

avVaa World Health Care Products Inc. (Pink Sheets: AVVH), a global biotechnology company, manufacturer and distributor of nationally branded therapeutic, natural skin and health care products, announced the results of its first DRTV test week.

15 Sep 2009

CPEX Pharmaceuticals to discuss the clinical aspects of nasal insulin therapy

CPEX Pharmaceuticals, Inc. (“CPEX”) today announced that it will participate in the Ninth Annual Diabetes Technology Meeting to be held November 5–7, 2009, at the Hyatt Regency Airport in San Francisco, California. Dr. Lance Berman, Senior Vice President and Chief Medical Officer, is scheduled to present an oral presentation titled “The Technology and Clinical Aspects of Nasal Insulin Therapy” at 9:30 a.m. PST on Saturday, November 7, 2009.

15 Sep 2009

HUYA Bioscience signs first-look agreement with Chinese Academy of Sciences' GIBH

HUYA Bioscience International, the leader in global pharmaceutical co-development with China, today announced a strategic partnership agreement with Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBH). HUYA has established a series of strategic partnerships with Chinese science institutes that affords it the opportunity to expand its portfolio of novel biopharmaceutical products.

15 Sep 2009

GlaxoSmithKline's Votrient will take significant market share away from Pfizer's Sutent by 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.

15 Sep 2009

A.P. Pharma and Merial sign license and development agreement for a long-acting pain management product

A.P. Pharma (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it has entered into a license and development agreement with Merial, a world leading animal health company, for a long-acting pain management product.

15 Sep 2009

FluCide more effective than Tamiflu

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that Anil Diwan, PhD, President of the Company presented a talk at NanoBusiness 2009 - the 8th annual NanoBusiness Conference in Chicago, IL, on Wednesday, September 9th.

15 Sep 2009

Forest Laboratories places Armour Thyroid medication on back order

Forest Laboratories, Inc., the maker of the widely used hormone therapy drug, Armour® Thyroid, recently announced it has placed the medication on back order. The company said on its website that it does not have enough of the active ingredient, powdered Thyroid gland, in stock to produce the medication.

15 Sep 2009

Wake Pharma to present clinical evidence in the treatment of wounds using Wound-Be-Gone at SAWC

Wake Pharma US announced today that clinical evidence in the treatment of wounds using Wound-Be-Gone® will be presented at the fall Society for Advance Wound Care Conference. The SAWC is being held in Washington, DC from September 16-18, 2009. The clinical evidence and data will be presented through posters on display during the meeting.

15 Sep 2009

Pharmaceutical News

Ganeden Biotech unveils the first quick dissolving, thin strip probiotic product

GENova Biotherapeutics and Prime BioResearch sign collaboration agreement

FDA grants orphan drug status to Advanced Life Sciences' Restanza

New book on pharmacology launched

Bavarian Nordic to deliver IMVAMUNE(R) vaccines

Four H1N1 vaccines approved by FDA

Pre-clinical studies of ID-12 orally-bioavailable inhibitor completes

New peptide-based cancer vaccine tested in genital cancer patients

Phase 3 clinical study results of bazedoxifene released

Idera Pharmaceuticals to discuss TLR-targeted drug discovery and development programs

Biocryst signs agreement with three partners to represent its anti-viral peramivir outside U.S.

Halozyme Therapeutics to present its product development pipeline

Neuroskin Psoriasis Relief DRTV test results announced by avVaa World Health Care

CPEX Pharmaceuticals to discuss the clinical aspects of nasal insulin therapy

HUYA Bioscience signs first-look agreement with Chinese Academy of Sciences' GIBH

GlaxoSmithKline's Votrient will take significant market share away from Pfizer's Sutent by 2018

A.P. Pharma and Merial sign license and development agreement for a long-acting pain management product

FluCide more effective than Tamiflu

Forest Laboratories places Armour Thyroid medication on back order

Wake Pharma to present clinical evidence in the treatment of wounds using Wound-Be-Gone at SAWC

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News